Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®.
generic viagra online
Application Of Innovative Laser Research Could Lead To Earlier Bone Disorder Diagnosis
A new laser technique that could lead to bone disorders being diagnosed earlier is to be tested in a hospital for the first time. The study, which it"s hoped will pave the way for future clinical trials, will apply a revolutionary approach known as SORS (Spatially Offset Raman Spectroscopy), to examine specific substances in non see-through surfaces deeper than has previously been possible, without damaging the surface. The research team hope ultimately that the method can be used both to detect and screen for early signs of diseases such as osteoarthritis and osteoporosis.
News of the day
Comment On Dimebolin (dimebon) Increasing Brain Beta Amyloid In Mouse Models
Dimebolin, originally administered as an antihistamine, has previously been found to help slow the decline of cognitive ability in participants.
Health Insurance

Reducing Drug Side-Effects In Pain Relief: New Research

They are a group of drugs which millions of people rely on to keep pain at bay but they can have unwanted side-effects which are sometimes more serious than the original health problem. Now scientists at The University of Nottingham are taking part in the largest-ever study on the safety of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) that has ever been performed. The project is called SOS (Safety Of non-Steroidal anti-inflammatory drugs) and will study the medical information of 35 million people in Europe to assess the incidence and nature of harmful side-effects on the cardiovascular and gastrointestinal systems of patients. It"s hoped the results will lead to better guidance for doctors on how to balance the advantages of prescribing the drugs with the associated risks of heart and digestive problems. NSAIDS are widely used in medicine for treating pain, inflammation and degenerative diseases like arthritis. The most commonly-used are aspirin and ibuprofen. But their use is associated with an increased risk of minor and serious gastrointestinal complications. It"s estimated that there are thousands of these cases in the European Union every year. Prompted by these problems, a new class of NSAIDS called "Coxibs" have been developed to reduce the risk of this type of side-effect, but the use of these new drugs has since been linked with an increased risk of heart problems such as heart attack and stroke. Clinicians and scientists now agree that the risk of stomach problems has to be balanced against the risk of cardiovascular interference. Both risks may differ in one person and for the 30 different types of NSAIDS available in the EU. Up to now research studies have been too small to be effective in terms of providing decision models for doctors and drug regulators but it"s hoped this new large survey will result in a much more accurate prescription method to minimize drug-related harm. Over the next two and a half years, published literature on previous clinical trials and observational studies will be scrutinized to identify any methodological inconsistencies and knowledge gaps and this information will be used to design and carry out an EU-wide observational study. This study will be the biggest of its kind ever undertaken in this field. It will include data from more than 35 million Europeans, taken from existing healthcare databases in the UK, the Netherlands, Germany and Italy. The researchers will use the data to create a variety of decision models to help doctors prescribe the most suitable type of NSAID for a particular patient and lower the risk of unwanted gastrointestinal or cardiovascular side-effects. The University of Nottingham is working with ten other leading European research institutions on the three-year project which is being funded with a 2.8 million Euros grant from the EC"s 7th Framework Programme. Fundamental to the project is QResearch, a not-for-profit partnership between The University of Nottingham and leading primary care system supplier EMIS, which uses data collected over the past 17 years. Professor of Clinical Epidemiology and General Practice, Julia Hippisley-Cox, who founded QResearch, said: "The SOS project will help quantify and compare the risks of different NSAIDs based on an individual"s profile and should help lead patients and doctors make better decisions regarding treatment options". Additional Information Project website: http://www.sos-nsaids-project.org Participating institutions: * Erasmus University Medical Centre, Netherlands * FundaciÃö IMIM, Spain * University of Nottingham, UK * Università di Milano-Bicocca, Italy * Research Triangle Institute, USA * Universitaet Bremen, Germany * The Research Institute of the McGill University Health Centre, Canada * Azienda Ospedaliera di Padova, Italy * PHARMO Cooperation UA, Netherlands * Université Victor-Segalen Bordeaux II, France * Azienda Sanitaria Locale della provincia di Cremona, Italy Professor Julia Hippisley-Cox University of Nottingham


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009